key: cord-0787960-l2jgd44f
authors: Rabec, Claudio; Gonzalez-Bermejo, Jesus
title: Respiratory support in patients with COVID-19 (outside ICU)
date: 2020-05-27
journal: Respir Med Res
DOI: 10.1016/j.resmer.2020.100768
sha: 2c91d01374ad50b1f5474dad5ac718897a86db7f
doc_id: 787960
cord_uid: l2jgd44f

Abstract With first cases noted towards the end of 2019 in China, COVID19 infection was rapidly become a devastating pandemic. Even if most patients present with a mild to moderate form of the disease, the estimated prevalence of COVID19-related severe acute respiratory failure (ARF) is 15-20% and 2-12% needed intubation and mechanical ventilation. In addition to mechanical ventilation some other techniques of respiratory support could be used in some forms of COVID19 related ARF. This position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases is intended to help respiratory clinicians involved in care of COVID19 pandemic in the rational use of non-invasive techniques such as oxygen therapy, CPAP, non-invasive ventilation and high flow oxygen therapy in managing patients outside ICU. The aims are: 1) to focus both on the place of each technique and in describing practical tips (types of devices and circuit assemblies) aimed to limit the risk of caregivers when using those techniques at high risk spreading of viral particles. 2) to propose a step-by-step strategy to manage ARF outside ICU

technique and in describing practical tips (types of devices and circuit assemblies) aimed to limit the risk of caregivers when using those techniques at high risk spreading of viral particles. 2) to propose a step-by-step strategy to manage ARF outside ICU The SARS-CoV-2 coronavirus has been identified as the agent of the pandemic known as COVID-19.

The first cases were noted towards the end of 2019 in Wuhan, China COVID-19 infection is spontaneously resolutive in most cases. The clinical presentation can vary from mild respiratory symptoms to severe pneumonia progressing to fulminant acute respiratory failure (ARF) (1). COVID-2019 pneumonia is characterized by bilateral infiltrates which can progress to diffuse alveolar condensations. In less severe patients, computed tomography (CT) shows bilateral ground glass sub pleural opacities (2) The estimated prevalence of COVID19-related acute respiratory failure (ARF) is 15-20% (1, 3, 4) .

In different published series, 41% had received O2,, 4-13% of patients non-invasive ventilation (NIV) and 2-12% needed intubation and mechanical ventilation (MV) (1, 3, 5-7).

In addition to MV some other techniques of respiratory support such as NIV, CPAP or high flow oxygen therapy (HFOT) could be used in some forms of ARF. Those techniques are currently applied in ICU but also in a pulmonary department. But the fact that this pandemics could go beyond the capacity of the health system, may lead that those techniques might be applied in less specialized services, These position paper is intended to help respiratory clinicians involved in care of COVID19 pandemic in managing patients outside ICU; They cannot be regarded as recommendations and reflect only authors experience during COVID19 pandemics, their expertise in the field of respiratory support and their critical review of the literature.

Oxygen should be used in case of severe CoVID19 pneumonia probably as soon as SpO2 <92% with a SpO2 target between 92 and 96%.

There are no randomized controlled studies concerning O2 in patients with COVID19 but is it possible to extrapolate data from studies in severe ARF. A meta-analysis of 25 randomized controlled studies has shown that a strategy with no upper limit on O2 flow ("liberal" approach) increases the risk of in-hospital death compared to a conservative ("targeted" approach) (8) .

This contrast with the results of a recent randomized controlled trial (RCT) comparing a "liberal" O2 therapy strategy (target SpO2> 96%) to a conservative one (target SpO2 >88% < 92%;). This study showed no difference in 28-days survival but an over mortality at 90 days in the conservative group (9) . Thus, based on those data, a target of >92 < 96% seems reasonable (10) There are no studies concerning the better interface to deliver O2. If available, it could be appropriate to use masks with filtered exhalation port (Filtamask or similar). Whatever the interface chosen, patient's comfort and decrease caregiver's risk will be prioritized when The interfaces used to deliver CPAP must be those available or those more familiar for the team. There is no advantage in using a helmet but remains an option, if available Circuits and masks must be adapted to reduce caregiver's risks (see figure 1) In hypoxemic ARF, applying an extrinsic PEEP increase alveolar recruitment and improves oxygenation. Furthermore, there is high level of evidence about the efficacy of adding PEEP during invasive ventilation in ARDS patients. Nevertheless, we lack information about the effectiveness of applying non-invasive PEEP. Experiences from Italian and Chinese teams are shared but not published.

As CPAP is easier to use that NIV, more available and need less expertise, this technique could be offered as a first line therapy in selected patients, as a gap to invasive MV, in particular when resources are limited or if there is no immediate access to invasive ventilation. A detail of CPAPdelivering devices, their limits and advantages is showed in Figure 1a .

In those cases NIV must be applied under a strict supervision of a trained physician. ICU team must be prevented and readily available NIV should be considered in patients who will not be admitted to ICU for intubation

The interfaces used to deliver NIV must be those available or those more familiar for the team.

There is no advantage in using a helmet but remains an option for expert teams Circuits and masks must be adapted to reduce caregiver's risks (see figure 2) There are no published data concerning NIV use outside ICU in patients with COVID19. NIV indications in ICU patients with COVID19-related ARF range from 11 to 34% (11) . Metaanalysis of RCT conducted in severe hypoxemic ARF showed that NIV could reduce the rate of intubation and mortality. However, they included patients with immunosuppression, acute heart failure (AHF) and post-operative ARF (7, (12) (13) (14) . Moreover, in ARF etiologies other than AHF, NIV has shown a high level of failure with higher mortality (28%) than those treated with O2 (23 %,) or HFOT (13%) (15), In a cohort of patients with Middle East respiratory syndrome, NIV was associated with better survival and a shorter length of stay (LOS) compared patients who were intubated without previous NIV. However, NIV showed a high failure rate (92.4%) requiring intubation (16) .

Finally, associating NIV and prone position reduced intubation in patients with moderate ARDS related to viral pneumonia. (17) On the other side, NIV could be harmful in those patents as it could worsen lung damage due to high pressures and high VT and could delay intubation (18, 19) Hence NIV could be considered as a first line therapy outside the ICU in particular when resources are limited or if there is no immediate access to invasive ventilation, In those cases NIV must be applied under a strict supervision of a trained physician to detect early and rapid worsening, a frequent condition in COVID19 pneumonia. ICU team must be prevented and readily available. When a patient is treated with NIV, monitoring should be intensified. If hypoxemia worsens the patient must be transferred to ICU if eligible for intubation. This decision will integrate not only the clinical severity, but also underlying pathologies and the "living wills" or end-of-life decisions (if available) of the patient and his family. This requires previous discussion on a case-by-case basis NIV should also be considered in patients no eligible to be admitted to ICU or in those with do not intubate (DNI) decision. In those cases, NIV must be continued only if it is well tolerated and a benefit is obtained. Otherwise, comfort measures only, including pharmacological measures, may be applied to relieve dyspnea (20) .

Some patients with underlying respiratory disease (COPD, obesity hypoventilation, restrictive disease) complicated with COVID19 pneumonia could benefit from de novo NIV In patients on long term NIV, treatment must be adapted during hospitalization, possibly by temporarily lowering the pressures if excessive leaks are present Circuits and masks must be adapted (Figure 2) When available a helmet interface could be applied. A randomized controlled study conducted in ARDS has shown that NIV when delivered by a helmet decrease intubation rate and mortality (21) . Moreover helmet limits viral spreading (22) .

It is imperative not to insist with NIV or O2 in patients that worsen. This can lead to a delay in intubation which can be fatal. Increased vigilance is necessary since muscle exhaustion is expressed late in those patients. In all cases, the intubation must be anticipated, carried out according to rigorous procedures and under conditions limiting the risk of caregivers.

As NIV is at high risk spreading of viral particles circuits and masks must be adapted to reduce caregiver's risks (14, 23, 24) . (see figure 2) 

As HFOT is at high risk spreading of viral particles, protective measures must be applied to reduce caregiver's exposition HFOT delivers a high-flow gas mixture (up to 70 l/min) with variable FiO2 (up to 100%) administered by a nasal cannula. Compared to conventional oxygen HFOT can ensure a constant and known FiO2. Other advantages are dead space reduction and generation of a low PEEP level allowing alveolar recruitment (25) .

There are no published data concerning HFOT in patients with COVID19 pneumonia.

In a RCT conducted in severe hypoxemic ARF, HFOT reduced 90-days mortality but not intubation rate compared to conventional oxygen (15) . Otherwise, a meta-analysis of 9 RCT shows a decrease in intubation rate but without improving survival or LOS (26) (27) (28) 

As nebulization is at high risk spreading of viral particles, nebulized treatments should be limited as much as possible.

Spray and powders should be preferred to provide inhaled therapy. If not possible, a minimal distance of 1 mt must be respected and the room must aerate during nebulization.

In the case of tracheostomized ventilator-dependent patients a "closed suction system" must be used"

The proposed flow chart strategy to manage ARF outside ICU in COVID19 patients is showed in Table 3 It is crucial to ensure an appropriate triage of patients at the admission. As those patients are at risk of early and rapid worsening, it seems reasonable that those with a rapidly progressive form (i.e presenting a SpO2< 94% and a RR > 30 while receiving > 6 lt O2) must be promptly assessed by the ICU staff to decide proper allocation

Step by step approach -Check and treat comorbidities -Begin conventional oxygen therapy by using nasal prongs to obtain the target RR and SpO2. 

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study

Clinical Characteristics of Coronavirus Disease 2019 in China

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis

Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response

Noninvasive versus invasive mechanical ventilation for immunocompromised patients with acute respiratory failure: a systematic review and meta-analysis

Noninvasive Ventilation in Acute Hypoxemic Nonhypercapnic Respiratory Failure: A Systematic Review and Meta-Analysis

Noninvasive Oxygenation Strategies in Immunocompromised Patients With Acute Hypoxemic Respiratory Failure: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials

High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure

Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza and Other Respiratory Viruses

Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study

Noninvasive ventilation for patients with hypoxemic acute respiratory failure. Seminars in Respiratory and Critical Care Medicine

Ventilator-induced lung injury

Withdrawing noninvasive ventilation at end-of-life care: is there a right time? Current Opinion in Supportive and Palliative Care

Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial

Exhaled air dispersion during noninvasive ventilation via helmets and a total facemask

Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation

Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features

High-Flow Nasal Cannula Oxygen in Adults: An Evidence-based Assessment

The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis

Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a meta-analysis of randomized controlled trials

High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis

Comparison of highflow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial

Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients